NCT02938585 - Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 12, 2016

Primary Completion Date

March 16, 2018

Study Completion Date

December 12, 2018

Conditions

Congenital Bleeding DisorderHaemophilia A

Interventions

DRUG

turoctocog alfa

The preventative treatment is administered intravenously (i.v.) at specific intervals either every second day or three times a week. Bleeding treatment will be administered if a bleed should occur.

DRUG

turoctocog alfa

Treatment is administered intravenously (i.v.) during bleeds and occasionally as a preventative treatment (e.g. before physical activity)

Trial Locations (11)

100045

Novo Nordisk Investigational Site, Beijing

200025

Novo Nordisk Investigational Site, Shanghai

300020

Novo Nordisk Investigational Site, Tianjin

310003

Novo Nordisk Investigational Site, Hangzhou

350001

Novo Nordisk Investigational Site, Fuzhou

400014

Novo Nordisk Investigational Site, Chonqqing

430030

Novo Nordisk Investigational Site, Wuhan

510515

Novo Nordisk Investigational Site, Guangzhou

550004

Novo Nordisk Investigational Site, Guiyang

650032

Novo Nordisk Investigational Site, Kunming

810007

Novo Nordisk Investigational Site, Xining